High VDR expression in stromal fibroblasts generally correlates with better outcomes, suggesting that even patients with low VDR-expressing tumor cells might benefit from VDR agonists if their stromal cells are adequately expressing VDR. This evidence concerns the gene VDR and neoplasm.